Join Dr. Madanat (UT Southwestern, Texas), Dr. Stahl (Harvard Medical School, Massachusetts), and Dr. Papadantonakis (Emory University, Georgia) as they break down key Myelodysplastic Syndromes (MDS) abstracts from the 2024 American Society of Hematology (ASH) meeting.

Tune in to gain valuable insights and stay informed about the evolving landscape of MDS management.

Dr. Rena Buckstein and Dr. Moshe Mittelman join Dr. Nikolaos Papadantonakis to discuss key MDS abstracts presented in the 2024 European Hematology Association Congress. Topics covered include anemia and the role of ivosidenib in higher risk MDS.

Dr. Nikolaos Papadantonakis discusses cytogenetics and mutational testing in MDS with Dr. Hetty Carraway and Dr. Moshe Mittelman and how they utilize this information in the clinical setting.

In this episode, Dr. Papadantonakis from Winship Cancer Institute of Emory University, Atlanta, US, and Dr. Mittelman, chairman of the MDS Foundation scientific board, discuss the range of treatment options for patients with MDS.

MDS experts Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss new trials presented in the last meeting of the American Society of Hematology (ASH) 2023. They focus on luspatercept, imetelstat and roxodustat.

Mrs. Iris Yahal, founder and director of MDS Israel Support Group (Israel MDS Foundation), discusses with Dr. Moshe Mittelman of Tel-Aviv, an MDS expert, several issues that are within the interest of MDS patients and families, including issues related to quality of life and the participation in clinical trials.

In this part I of the frequently asked questions episode, Mrs. Iris Yahal, the founder and director of the MDS Israel Support Group (Israel MDS foundation), asks and discusses with Dr. Mittelman, of Tel-Aviv, several topics that are within the interest of patients and families. The questions of MDS as an inherited disease or as a cancer, as well as issues related to patient-physician relationship, are discussed.

Moshe Mittelman, Professor of Medicine and Hematology from Tel-Aviv and chairman, the scientific board of MDS Foundation, interviews Mrs. Noa Goldschmidt, Chief Study Coordinator in Tel-Aviv Sourasky Medical Center, about clinical trials from the perspective of patients and families. They discuss several issues, include the three phases of trial, why the patients benefit from trials and other important points.

In this episode of the MDS-Foundation Podcast Projects – The Patient and Families
Program, Dr. Moshe Mittelman, Chief MDS Center of Excellence, Tel Aviv Sourasky
(Ichilov) Medical Center, Tel-Aviv, and Mrs. Noa Goldshmidt, Chief Study Coordinator
at TASMC, discussing various issues related to clinical trials. The episode is directed
to MDS patients, their families, and all interested parties, with a special focus on
clinical trials for MDS patients. Among other topics, they explain what clinical trials
are, why they are so important, they describe the stages and process of clinical
trials, and explain why patients can benefit from participation in trials. Finally, they
emphasize that patient safety is the prior interest and is highly maintained, and
provide some interesting real-world examples.

Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss the role of blood transfusions and issues related to quality of life in patients with myelodysplastic syndromes (MDS), including reviewing the recent research in the field.